Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

N/A

2(33.3%)

Phase 1

1(16.7%)

Phase 3

1(16.7%)

Phase 4

1(16.7%)

Phase 2

1(16.7%)

6Total

N/A(2)

Phase 1(1)

Phase 3(1)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07296276Not ApplicableRecruiting

Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

Role: collaborator

NCT05806554Completed

Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial

Role: collaborator

NCT05408663Phase 1Completed

A Phase 1 Study of EXT608 in Healthy Adults

Role: collaborator

NCT04398030Not ApplicableCompleted

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

Role: collaborator

NCT05348928Completed

A Pilot Study of the Feasibility and Accuracy of the TrueVie CGM System - A Non-Significant Risk Study

Role: collaborator

NCT03490942Phase 2Terminated

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

Role: collaborator

NCT03439072Phase 3Completed

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Role: collaborator

NCT02789319Phase 4Completed

DTS Blood Glucose Monitor System Surveillance Program SubStudy 1

Role: collaborator

NCT01326598Completed

Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting

Role: collaborator

All 9 trials loaded